Metastasis and chemoresistance remain major challenges in the clinical treatment of breast cancer. Recent studies show that dysregulated microRNAs (miRNAs) play an important role in metastasis and chemoresistance development in breast cancer.
carcinoma pathogenesis to drive epithelial cells towards a mesenchymal state. 4 Hyperactivated EMT is often detected during cancer progression, and aberrantly activated EMT enables the cells forming these tumors to acquire the traits of highly malignant cells, notably, motility, invasiveness and an ability to disseminate to form distant metastases. 4 In addition, recent studies show that cancer cells that have undergone EMT acquire cancer stem cell properties, thereby significantly contributing to the development of chemoresistance. 5 Thus, the EMT pathway is of great therapeutic interest in the treatment of cancers, including breast cancer. In fact, studies show that targeting EMT can abrogate chemoresistance 6 and inhibit cancer metastasis. 7 Studies show that many factors, including microRNAs (miRNAs), are involved in the regulation of EMT. [8] [9] [10] miRNAs are small non-coding RNA molecules that inhibit target gene expression at the post-transcriptional level by directly binding to a target gene's 3 0 -UTR. 11 Studies show that miRNA expression was dysregulated in many cancers and that dysregulated miRNAs lead to aberrant expression of their target genes, thereby contributing to all stages of cancer progression. [12] [13] [14] [15] [16] Accumulating evidence shows that dysregulated miRNAs are also involved in the activation of EMT in cancer. 10, 17 Studies show that dysregulated miRNAs induce EMT partly through targeting EMT stimulators, including ZEB1, 9 CDH2, 18 N-cadherin, 19 and vimentin. 20 In the present study, we identified downregulated expression of miR-708-3p in specimens from breast cancer patients, and our data
show that decreased expression of miR-708-3p was significantly associated with breast cancer metastasis. Additionally, we found that overexpression of miR-708-3p inhibited metastasis and enhanced chemosensitivity of breast cancer cells. Furthermore, we identified that miR-708-3p inhibited EMT by directly targeting EMT activators, including ZEB1, CDH2 and vimentin. Our findings clearly show that miR-708-3p acts as a cancer suppressor and that it carries out its anti-cancer role by inhibiting EMT in breast cancer. Additionally, restoration of miR-708-3p may be a novel strategy for treating breast cancer patients with metastasis or chemoresistance. Firefly luciferase activity was normalized by the activity of Renilla luciferase.
| MATERIALS AND METHODS

| Reagents
| Luciferase reporter assay
| Western blot and immunohistochemistry assays
Western blotting and immunohistochemical assays were carried out as described by Xu et al. 21 2.6 | MTT assay and apoptotic cell detection 
| Invasion assay
Cells were transfected with the indicated oligonucleotides for 48 hours, and then, 1 9 10 4 cells in growth medium without serum were seeded in the upper wells of BD Chambers. The lower wells contained the same medium with 10% serum. After 24 hours, the cells that had invaded the lower side of the chamber were fixed with 2.5% glutaraldehyde, stained with 0.1% crystal violet, dried and counted.
| Stable cell line selection
A miR-708-3p expression vector was constructed using a BLOCK-iT Care and Use Committee of the Chuncheon Sacred Heart Hospital.
| Statistical analysis
All data are presented as the mean AE standard deviation (SD), and significant differences between treatment groups were analyzed by Student's t test or one-way analysis of variance (ANOVA) and Duncan's multiple range test using SAS statistical software version 6.12
(SAS Institute). Differences were considered statistically significant at a P-value of <.05.
3 | RESULTS
| Decreased expression of miR-708-3p was correlated with metastasis in breast cancer
Solexa (Illumina) deep-sequencing data show that miR-708-3p expression was decreased in the metastatic breast cancer cell line MDA-MB-231 compared to that in the non-cancerous mammary epithelial cell line MCF-10A. 22 However, the function and expression level of miR-708-3p in breast cancer patients are unknown. Thus, we first investigated the expression of miR-708-3p in human breast tumors. Our data showed that miR-708-3p expression was significantly decreased in breast cancer specimens compared to that in their matched adjacent normal tissues ( Figure 1A ). In addition, we found that miR-708-3p expression was more significantly decreased in specimens from breast cancer patients with lymph node metastasis compared to those from breast cancer patients with no metastasis (Figure 1B,C; Table 1 ). However, clinicopathological features, such as progesterone receptor (PR), estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) status, were not significantly associated with miR-308-3p level (Table 1) . Consistent with clinical data, in vitro experiments also showed that miR-708-3p
was significantly downregulated in aggressive breast cancer cell lines ( Figure 1D ). Taken together, these findings suggest that decreased expression of miR-708-3p was significantly correlated with breast cancer metastasis.
| Inhibition of miR-708-3p stimulates breast cancer cell metastasis
To investigate whether decreased expression of miR-708-3p was involved in breast cancer cell metastasis, we inhibited miR-708-3p using antisense nucleotides of miR-708-3p (ASO miR-708-3p) in a cell line with high expression of miR-708-3p (MCF-7) (Figure 2A) and then carried out invasion assays. Our results showed that inhibition of miR-708-3p significantly stimulated MCF-7 cell invasion (Figure 2B ). This result was confirmed using another cell line, MDA-MB-468, and results similar to those seen in the MCF-7 cell line were observed ( Figure 2B ). Furthermore, to confirm these in vitro results in vivo, we used MDA-MB-468 cells that stably express antisense miR-708-3p to generate a breast cancer lung metastasis model ( Figure 2A ) and determined the number of tumor nodules on the F I G U R E 1 MicroRNA-708-3p (miR-708-3p) expression level was negatively correlated with metastasis in breast cancer. A, miR-708-3p expression was significantly decreased in human breast tumor tissues compared to that in matched adjacent normal tissues (n = 30). B, miR-708-3p expression was significantly decreased in specimens from breast cancer patients with metastasis (n = 20) compared to that in specimens from breast cancer patients with no metastasis (n = 30). C, Correlation of miR-708-3p expression level with metastasis in breast cancer patients. D, miR-708-3p expression level was negatively correlated with invasiveness in breast cancer cell lines. miR-708-3p expression was measured using RT-qPCR in specimens and breast cancer cell lines. *P < .05; ***P < .001 LEE ET AL. 
F I G U R E 2
Inhibition of microRNA-708-3p (miR-708-3p) significantly stimulated breast cancer cell metastasis. A, miR-708-3p expression was significantly decreased in miR-708-3p antisense nucleotide (ASO miR-708-3p)-transfected or stably expressing miR-708-3p antisense breast cancer cells. The indicated cells were transfected with indicated nucleotides or plasmid and, then, the expression of miR-708-3p was measured by RT-qPCR after 72 h of transfection. B, Inhibition of miR-708-3p significantly stimulated cell invasion in both MCF-7 and MDA-MB-468 breast cancer cells. Indicated cells were transfected with negative control oligonucleotides (NC) or ASO miR-708-3p. After 48 h of transfection, the cells were subjected to invasion assays. C, Inhibition of miR-708-3p significantly stimulated MDA-MB-468 cell lung metastasis. Stably expressing miR-708-3p antisense breast cancer cells or their vector control cells were injected into nude mice through the tail vein. After 1 mo of cell injection, the mice were killed, and their lungs were collected. D, Tumor nodules on the lung surface were counted. *P < .05; ***P < .001
| miR-708-3p inhibits EMT in breast cancer cells
Epithelial-to-mesenchymal transition plays an important role in breast cancer cell metastasis. Thus, herein, we investigated whether miR-708-3p is involved in the regulation of breast cancer cell EMT. 
| miR-708-3p inhibits EMT by targeting EMT stimulators
To investigate the underlying mechanism of the effect of miR-708-3p on breast cancer cell EMT, we used miRNA target prediction algorithms (targetscan.org and mirdb.org) to screen for miR-708-3p
target genes, and we identified ZEB1, CDH2 and vimentin as tenta- well-defined stimulators of EMT in breast cancer, and our target prediction results showed that these genes contain the binding sequence of miR-708-3p ( Figure 5A ). To investigate the association F I G U R E 3 Overexpression of microRNA-708-3p (miR-708-3p) significantly inhibited breast cancer cell metastasis. A, miR-708-3p expression was significantly increased in miR-708-3p mimic transfected or stably expressing miR-708-3p breast cancer cells. The indicated cells were transfected with negative control nucleotides (NC) or miR-708-3p mimics and, then, the expression of miR-708-3p was measured using RT-qPCR after 72 h of transfection. B, Overexpression of miR-708-3p significantly inhibited cell invasion in both MDA-MB-231 and MDA-MB-468 breast cancer cells. The indicated cells were transfected with NC or miR-708-3p mimics. After 48 h of transfection, the cells were subjected to invasion assays. C, Overexpression of miR-708-3p significantly inhibited MDA-MB-468 cell lung metastasis. Stably expressing miR-708-3p breast cancer cells or their vector control cells were injected into nude mice through the tail vein. After 1 mo of cell injection, the mice were killed, and their lungs were collected. D, Tumor nodules on the lung surface were counted. *P < .05; **P < .01
between miR-708-3p and target gene expression, we examined the expression levels of these target genes in miR-708-3p-overexpressing or miR-708-3p-inhibited MDA-MB-468 breast cancer cells. As shown in Figure 5B ,C, the expression of ZEB1, CDH2 and vimentin was significantly decreased in miR-708-3p-overexpressing cells at both the mRNA and protein levels compared to that in vector control cells. In contrast, inhibition of miR-708-3p led to an increase in the expression of ZEB1, CDH2 and vimentin at both the mRNA and protein levels ( Figure 5B,C) . Next, to determine whether the regulation of the expression of target luciferase reporter genes depended on binding of their complementary 3 0 -UTR sequences to the miR-708-3p seed sequence, a 3-nucleotide mutation was inserted into the 3 0 -UTR of the target genes, as indicated in Figure 5A . Our data showed that overexpression or inhibition of miR-708-3p significantly repressed or increased the luciferase activity associated with the wild-type 3 0 -UTR, respectively. However, the 3 0 -UTR mutation completely abrogated the effect of miR-708-3p overexpression or inhibition on luciferase activity in MDA-MB-468 cells ( Figure 5D ).
Cumulatively, these data suggest that miR-708-3p negatively regulates the expression of ZEB1, CDH2 and vimentin in breast cancer cells by directly targeting their 3 0 -UTR sequence.
| miR-708-3p enhances chemosensitivity of breast cancer cells
Previous studies have shown that EMT plays a key role in the chemoresistance of breast cancer, 26 and our data showed that miR-708-3p is involved in the regulation of EMT. Thus, herein, we investigated the effects of miR-708-3p on the chemosensitivity of breast cancer cells. As shown Figure 6A , inhibition of miR-708-3p sup- assay results also showed that combination treatment more significantly induced apoptosis than other treatments ( Figure 6D ). Taken together, these findings suggest that miR-708-3p is negatively correlated with chemoresistance in breast cancer and that the restoration of miR-708-3p may be a useful strategy for enhancing chemosensitivity for the treatment of breast cancer.
| DISCUSSION
Metastasis and chemoresistance are important prognostic factors and are associated with poor survival in patients with breast cancer. 27 Regarding breast cancer, although extensive studies concerning its intricate molecular mechanisms are ongoing, development of novel therapies and more accurate diagnostic and prognostic approaches is still a challenge. 28 Herein, we identified that the expression of miR-708-3p was remarkably decreased in specimens from breast cancer patients with metastasis compared to specimens from patients with no metastasis. In addition, in vitro data showed that the expression level of miR-708-3p was negatively correlated with invasiveness in breast cancer cell lines, suggesting that miR-708-3p expression level may be a candidate biomarker for predicting breast cancer metastasis. Additionally, we demonstrated a crucial role for miR-708-3p in breast cancer metastasis and chemosensitivity. Our in vitro and in vivo experimental data clearly suggested that decreased expression of miR-708-3p significantly stimulated breast cancer cell metastasis and the development of chemoresistance.
Notably, our investigation further discovered that ectopic expression of miR-708-3p significantly inhibited metastasis and enhanced the sensitivity of chemotherapy in breast cancer both in vitro and in vivo, thus suggesting that ectopic expression of miR-708-3p may be a novel strategy for inhibiting metastasis and enhancing the chemosensitivity of breast cancer.
In the present study, we also clarified the tumor inhibition mechanism of miR-708-3p in breast cancer. EMT occurs when epithelial cells lose their connections with their environment and achieve a started. D, Combination of miR-708-3p and doxorubicin more significantly induced apoptosis than vehicle control and single drug treatments in xenograft tumors. TUNEL assay was carried out for the detection of apoptotic cells in tumor tissues from the MDA-MB-231 xenograft model. *P < .05; **P < .01; ***P < .001. NC, negative control oligonucleotides
